'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma

Systematic review

I. Abraham, A. Alhossan, Christopher Lee, H. Kutbi, K. Macdonald

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

We reviewed 24 'real-life' effectiveness studies of omalizumab in the treatment of severe allergic asthma that included 4117 unique patients from 32 countries with significant heterogeneity in patients, clinicians and settings. The evidence underscores the short- and long-term benefit of anti-IgE therapy in terms of the following: improving lung function; achieving asthma control and reducing symptomatology, severe exacerbations and associated work/school days lost; reducing healthcare resource utilizations, in particular hospitalizations, hospital lengths of stay and accident specialist or emergency department visits; reducing or discontinuing other asthma medications; and improving quality of life - thus confirming, complementing and extending evidence from randomized trials. Thus, omalizumab therapy is associated with signal improvements across the full objective and subjective burden of illness chain of severe allergic asthma. Benefits of omalizumab may extend up to 2-4 years, and the majority of omalizumab-treated patients may benefit for many years. Omalizumab has positive short- and long-term safety profiles similar to what is known from randomized clinical trials. Initiated patients should be monitored for treatment response at 16 weeks. Those showing positive response at that time are highly likely to show sustained treatment response and benefit in terms of clinical, quality of life and health resource utilization outcomes.

Original languageEnglish (US)
JournalAllergy: European Journal of Allergy and Clinical Immunology
DOIs
StateAccepted/In press - 2016

Fingerprint

Asthma
Length of Stay
Quality of Life
Therapeutics
Cost of Illness
Health Resources
Accidents
Hospital Emergency Service
Hospitalization
Randomized Controlled Trials
Omalizumab
Delivery of Health Care
Safety
Lung

Keywords

  • Allergic asthma
  • Effectiveness
  • IgE
  • Omalizumab
  • Systematic review

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma : Systematic review. / Abraham, I.; Alhossan, A.; Lee, Christopher; Kutbi, H.; Macdonald, K.

In: Allergy: European Journal of Allergy and Clinical Immunology, 2016.

Research output: Contribution to journalArticle

@article{65f20121b52e4de0a25572e1f4239797,
title = "'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: Systematic review",
abstract = "We reviewed 24 'real-life' effectiveness studies of omalizumab in the treatment of severe allergic asthma that included 4117 unique patients from 32 countries with significant heterogeneity in patients, clinicians and settings. The evidence underscores the short- and long-term benefit of anti-IgE therapy in terms of the following: improving lung function; achieving asthma control and reducing symptomatology, severe exacerbations and associated work/school days lost; reducing healthcare resource utilizations, in particular hospitalizations, hospital lengths of stay and accident specialist or emergency department visits; reducing or discontinuing other asthma medications; and improving quality of life - thus confirming, complementing and extending evidence from randomized trials. Thus, omalizumab therapy is associated with signal improvements across the full objective and subjective burden of illness chain of severe allergic asthma. Benefits of omalizumab may extend up to 2-4 years, and the majority of omalizumab-treated patients may benefit for many years. Omalizumab has positive short- and long-term safety profiles similar to what is known from randomized clinical trials. Initiated patients should be monitored for treatment response at 16 weeks. Those showing positive response at that time are highly likely to show sustained treatment response and benefit in terms of clinical, quality of life and health resource utilization outcomes.",
keywords = "Allergic asthma, Effectiveness, IgE, Omalizumab, Systematic review",
author = "I. Abraham and A. Alhossan and Christopher Lee and H. Kutbi and K. Macdonald",
year = "2016",
doi = "10.1111/all.12815",
language = "English (US)",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0108-1675",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma

T2 - Systematic review

AU - Abraham, I.

AU - Alhossan, A.

AU - Lee, Christopher

AU - Kutbi, H.

AU - Macdonald, K.

PY - 2016

Y1 - 2016

N2 - We reviewed 24 'real-life' effectiveness studies of omalizumab in the treatment of severe allergic asthma that included 4117 unique patients from 32 countries with significant heterogeneity in patients, clinicians and settings. The evidence underscores the short- and long-term benefit of anti-IgE therapy in terms of the following: improving lung function; achieving asthma control and reducing symptomatology, severe exacerbations and associated work/school days lost; reducing healthcare resource utilizations, in particular hospitalizations, hospital lengths of stay and accident specialist or emergency department visits; reducing or discontinuing other asthma medications; and improving quality of life - thus confirming, complementing and extending evidence from randomized trials. Thus, omalizumab therapy is associated with signal improvements across the full objective and subjective burden of illness chain of severe allergic asthma. Benefits of omalizumab may extend up to 2-4 years, and the majority of omalizumab-treated patients may benefit for many years. Omalizumab has positive short- and long-term safety profiles similar to what is known from randomized clinical trials. Initiated patients should be monitored for treatment response at 16 weeks. Those showing positive response at that time are highly likely to show sustained treatment response and benefit in terms of clinical, quality of life and health resource utilization outcomes.

AB - We reviewed 24 'real-life' effectiveness studies of omalizumab in the treatment of severe allergic asthma that included 4117 unique patients from 32 countries with significant heterogeneity in patients, clinicians and settings. The evidence underscores the short- and long-term benefit of anti-IgE therapy in terms of the following: improving lung function; achieving asthma control and reducing symptomatology, severe exacerbations and associated work/school days lost; reducing healthcare resource utilizations, in particular hospitalizations, hospital lengths of stay and accident specialist or emergency department visits; reducing or discontinuing other asthma medications; and improving quality of life - thus confirming, complementing and extending evidence from randomized trials. Thus, omalizumab therapy is associated with signal improvements across the full objective and subjective burden of illness chain of severe allergic asthma. Benefits of omalizumab may extend up to 2-4 years, and the majority of omalizumab-treated patients may benefit for many years. Omalizumab has positive short- and long-term safety profiles similar to what is known from randomized clinical trials. Initiated patients should be monitored for treatment response at 16 weeks. Those showing positive response at that time are highly likely to show sustained treatment response and benefit in terms of clinical, quality of life and health resource utilization outcomes.

KW - Allergic asthma

KW - Effectiveness

KW - IgE

KW - Omalizumab

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84959420164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959420164&partnerID=8YFLogxK

U2 - 10.1111/all.12815

DO - 10.1111/all.12815

M3 - Article

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0108-1675

ER -